Non-alcoholic fatty liver disease fibrosis score and preclinical vascular damage in morbidly obese patients

详细信息    查看全文

• 作者：Alessandra Gentili^a ; ^{alessandra.gentili1987@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Giulia Daviddi^a ; Stefano De Vuono^a ; Maria Anastasia Ricci^a ; Francesco Di Filippo^a ; Abdalkader Alaeddin^a ; Massimo R. Mannarino^a ; Marcello Boni^b ; Gaetano Vaudo^a ; Graziana Lupattelli^a
• 关键词：Cardiovascular disease ; Morbid obesity ; Preclinical atherosclerosis
• 刊名：Digestive and Liver Disease
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：48
• 期：8
• 页码：904-908
• 全文大小：422 K

文摘

Non-alcoholic fatty liver disease (NAFLD) is strongly related with enhanced morbidity and mortality from cardiovascular disease. In obese patients with both NAFLD and features of the metabolic syndrome, the cardiovascular risk is further increased.

Aim

The aim of this study is to investigate the relationship between severity of liver fibrosis evaluated by NAFLD fibrosis score (NAFLD-FS), Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), other obesity-related markers and preclinical atherosclerosis in morbidly obese patients with previously diagnosed NAFLD.

Methods

Laboratory parameters, visceral fat area (VFA), flow-mediated dilatation (FMD), intima-media thickness (IMT), HOMA-IR and NAFLD-FS were determined in 196 morbidly obese patients.

Results

Patients with higher NAFLD-FS or HOMA-IR show higher left max-IMT and lower FMD (p < 0.001). VFA and NAFLD-FS, but not HOMA-IR, were independent predictors of reduced FMD (respectively β −0.268, p = 0.001 and β −0.165, p = 0.039, p of the model < 0.001) and increased left max-IMT (respectively β 0.165, p = 0.031 and β 0.301, p < 0.001, p of the model < 0.001).

Conclusions

In morbidly obese patients, NAFLD-FS correlates with markers of early vascular damage. NAFLD-FS, easier to obtain than VFA, seems to be a better score than HOMA-IR to categorize such subjects who are potentially at risk of future cardiovascular events.